We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01074931
First Posted: February 24, 2010
Last Update Posted: August 3, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Abbott
Results First Submitted: May 20, 2011  
Study Type: Observational
Study Design: Time Perspective: Prospective
Condition: HIV-1 Infections
Intervention: Drug: Lopinavir/ritonavir (Kaletra)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Lopinavir/Ritonavir Group Adult participants with HIV-1 infection taking lopinavir/ritonavir

Participant Flow:   Overall Study
    Lopinavir/Ritonavir Group
STARTED   98 
COMPLETED   92 
NOT COMPLETED   6 
Economic reasons                1 
Death                5 



  Baseline Characteristics


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Evolution of the HIV Viral Response   [ Time Frame: Month 3, 6, 12, 18 ]

2.  Primary:   Evolution of CD4 Count   [ Time Frame: Month 3, 6, 12, 18 ]

3.  Primary:   Evolution of the Tolerance Issues   [ Time Frame: Month 3, 6, 12, 18 ]

4.  Secondary:   Number of Participants Who Missed Doses, Interrupt or Discontinue Regimen, and Experience Changes in Dosage or of Combination Regimen   [ Time Frame: Month 3, 6, 12, 18 ]

5.  Secondary:   Adverse Events Observed and Development of Lipodystrophy Lesion and Their Locations   [ Time Frame: Month 3, 6, 12, 18 ]

6.  Secondary:   The Duration on Treatment Until Development of an Adverse Event Leading to Treatment Discontinuation or Until Escape From Treatment   [ Time Frame: Month 3, 6, 12, 18 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The location of lipodystrophy was not summarized as there was not a place to record the information on the case report form. Too few participants withdrew from treatment to conduct planned analyses of duration to adverse event(s)/discontinuation.


  More Information